Autoimmune Disease News and Research

RSS

Autoimmune Disease is a condition in which the body recognizes its own tissues as foreign and directs an immune response against them.

Ambit commences Phase I advanced solid tumor trials for AC430 and AC480 inhibitors

Ambit Biosciences, today announced that it has initiated separate Phase I trials for two products AC430, a selective Janus Kinase 2 (JAK2) inhibitor, and AC480, a pan-HER inhibitor.

20 Dec 2010

Isotechnika, Paladin receive screening acceptance for Voclera for approval in Canada

Isotechnika Pharma Inc. and Paladin Labs Inc. announced today that they have submitted the dossier and received screening acceptance for VocleraTM (voclosporin) for approval in the Canadian market. VocleraTM is a novel immunosuppressive drug in the class of calcineurin inhibitors and is indicated for the treatment of moderate to severe psoriasis.

20 Dec 2010

Study reveals immune cell provides new therapeutic strategy for SLE

A new study provides fascinating insight into the underlying pathology associated with the autoimmune disease, systemic lupus erythematosus.

16 Dec 2010

CGEN-15001 administration shows dramatic therapeutic potential in CIA animal model

Compugen Ltd. announced today that administration of CGEN-15001 in an animal model of rheumatoid arthritis dramatically ameliorates the clinical symptoms of the disease.

15 Dec 2010

Lexicon reports top-line results from LX2931 Phase 2a study in rheumatoid arthritis

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced top-line results from a recently completed Phase 2a study of LX2931 in patients with rheumatoid arthritis (RA). LX2931 is an orally-delivered, small molecule drug candidate that inhibits sphingosine-1-phosphate (S1P) lyase, an enzyme important for modulating the immune system by controlling S1P levels in lymphoid tissues.

14 Dec 2010

Immunomedics, UCB initiate enrollment in EMBODY 1 epratuzumab Phase III study in SLE

Immunomedics Inc. and UCB today announced the enrollment of the first patient into EMBODY™ 1, one of two pivotal Phase III studies of epratuzumab in patients with moderate to severe systemic lupus erythematosus (SLE). Patient enrollment for EMBODY™ 2 has also begun.

14 Dec 2010

Research: Kidney disease caused by autoimmune disease lupus may be twice as lethal in children

Kidney disease caused by the autoimmune disease lupus may be twice as lethal in children as kidney disease caused by other disorders, according to research led by Johns Hopkins Children's Center investigators.

13 Dec 2010

TRL, Anaphore partner to develop novel protein therapies for autoimmune diseases

Tanabe Research Laboratories U.S.A. Inc., (TRL) announced today that it has entered into a partnership with Anaphore Inc. for the research and preclinical development of novel protein therapies for autoimmune diseases based on Anaphore's proprietary Atrimer™ technology.

13 Dec 2010

New NIH guidelines support broader use of blood tests to diagnose food allergy

New guidelines on diagnosis and management of food allergy issued by the National Institute of Allergy and Infectious Diseases a part of NIH, supports a broader use of blood test to improve current clinical practice. Phadia's ImmunoCAP is recognized for its superior predictive values compared to other systems. It provides precise, quantitative and standardized results and help doctors make an accurate diagnosis.

8 Dec 2010

$Seattle Genetics and Millennium announce positive data from SGN-35 Phase II trial in relapsed or refractory ALCL$

Seattle Genetics and Millennium announce positive data from SGN-35 Phase II trial in relapsed or refractory ALCL

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced positive data from a phase II clinical trial of single-agent brentuximab vedotin (SGN-35) in relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). Brentuximab vedotin is an antibody-drug conjugate (ADC) targeted to CD30, a defining marker of ALCL. The data were presented today during an oral session at the 52nd American Society of Hematology (ASH) Annual Meeting in Orlando, FL.

7 Dec 2010

$Positive results from pivotal trial of SGN-35 in refractory Hodgkin lymphoma presented at ASH 2010$

Positive results from pivotal trial of SGN-35 in refractory Hodgkin lymphoma presented at ASH 2010

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced positive results from the pivotal trial of single-agent brentuximab vedotin (SGN-35) in relapsed or refractory Hodgkin lymphoma. Brentuximab vedotin is an antibody-drug conjugate targeted to CD30, a defining marker of Hodgkin lymphoma.

6 Dec 2010

Researchers adapt gene chip microarray technology to study glycans

Sugar molecules coat every cell in our bodies and play critical roles in development and disease, yet the components of these "glycans" have been difficult for scientists to study, because of their complexity.

6 Dec 2010

HSS creates Center for Musculoskeletal Outcomes and Patient Oriented Research

Hospital for Special Surgery announced the creation of the Center for Musculoskeletal Outcomes and Patient Oriented Research to translate information collected from an extensive patient population into studies that will guide experts in preventing, diagnosing and treating musculoskeletal disorders.

4 Dec 2010

FDA Advisory Committee votes in favor of expanded use of LAP-BAND gastric band

Allergan, Inc. (NYSE: AGN) today announced the U.S. Food and Drug Administration (FDA) Gastroenterology and Urology Devices Panel of the Medical Devices Advisory Committee has recommended with an 8-2 vote that the FDA extend the currently approved use of the LAP-BAND® System, Allergan's gastric band, on the basis of a favorable benefit-risk profile for weight reduction in obese adults who have failed more conservative weight reduction alternatives and have a Body Mass Index (BMI) of at least 35 or a BMI ≥30 and at least one comorbid condition.

4 Dec 2010

Merck plans to acquire SmartCells

Today pharmaceutical company, Merck & Co., Inc. announced it will acquire SmartCells, Inc., a private biotech developing a glucose-responsive insulin whose proof-of-concept preclinical trials were partially funded by the Juvenile Diabetes Research Foundation.

4 Dec 2010

FDA extends PDUFA review target date for BENLYSTA BLA to treat systemic lupus erythematosus

Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) target date for its priority review of the Biologics License Application (BLA) for BENLYSTA® (belimumab) as a potential treatment for systemic lupus erythematosus (SLE) from December 9, 2010 to March 10, 2011.

4 Dec 2010

HSS creates Center for Musculoskeletal Outcomes and Patient Oriented Research

Hospital for Special Surgery (HSS) announced the creation of the Center for Musculoskeletal Outcomes and Patient Oriented Research to translate information collected from an extensive patient population into studies that will guide experts in preventing, diagnosing and treating musculoskeletal disorders.

2 Dec 2010

Are vitamin D and calcium supplements needed?

The IOM raised the recommended dietary allowance of vitamin D from the amount cited in their last report, released 13 years ago. It said that although 600 international units (IUs) of vitamin D or more each day is sufficient to maintain bone health in majority. But those aged 71 and older may need as much as 800 IUs daily, the IOM experts say. However 1997 recommendations advised 400 IUs per day for people aged 51 to 70 and 600 IUs per day for those over 70.

30 Nov 2010

First-ever selective irreversible inhibition of viral protease using targeted covalent drug

Avila Therapeutics, Inc., a biotechnology company developing novel targeted covalent drugs, has published research in Nature Chemical Biology demonstrating the first-ever selective irreversible inhibition of a viral protease using a targeted covalent drug.

30 Nov 2010

Accentia enters strategic agreement with Baxter to purchase Cytoxan drug

Accentia Biopharmaceuticals, Inc. today announced a strategic agreement with Baxter Healthcare Corporation to provide Accentia with the exclusive, worldwide right to purchase Baxter's cyclophosphamide, which is marketed under the brand name Cytoxan, for the treatment of designated autoimmune diseases including multiple sclerosis.

29 Nov 2010

Autoimmune Disease News and Research

Further Reading

Ambit commences Phase I advanced solid tumor trials for AC430 and AC480 inhibitors

Isotechnika, Paladin receive screening acceptance for Voclera for approval in Canada

Study reveals immune cell provides new therapeutic strategy for SLE

CGEN-15001 administration shows dramatic therapeutic potential in CIA animal model

Lexicon reports top-line results from LX2931 Phase 2a study in rheumatoid arthritis

Immunomedics, UCB initiate enrollment in EMBODY 1 epratuzumab Phase III study in SLE

Research: Kidney disease caused by autoimmune disease lupus may be twice as lethal in children

TRL, Anaphore partner to develop novel protein therapies for autoimmune diseases

New NIH guidelines support broader use of blood tests to diagnose food allergy

Seattle Genetics and Millennium announce positive data from SGN-35 Phase II trial in relapsed or refractory ALCL

Positive results from pivotal trial of SGN-35 in refractory Hodgkin lymphoma presented at ASH 2010

Researchers adapt gene chip microarray technology to study glycans

HSS creates Center for Musculoskeletal Outcomes and Patient Oriented Research

FDA Advisory Committee votes in favor of expanded use of LAP-BAND gastric band

Merck plans to acquire SmartCells

FDA extends PDUFA review target date for BENLYSTA BLA to treat systemic lupus erythematosus

HSS creates Center for Musculoskeletal Outcomes and Patient Oriented Research

Are vitamin D and calcium supplements needed?

First-ever selective irreversible inhibition of viral protease using targeted covalent drug

Accentia enters strategic agreement with Baxter to purchase Cytoxan drug

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News